Virax Biolabs Group Limited (VRAX)

Healthcare | Biotechnology
Income Statement (Quarterly) 2024-09-30 2024-03-31 2023-09-30 2023-03-31
Revenue 4,953 79,919 76,500 2,801
Cost of Revenue 11,427 39,847 65,982 4,284
Gross Profit -6,474 40,072 10,518 -1,483
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 2,146,005 2,287,297 2,307,446 3,990,215
Operating Expenses 2,872,417 3,830,322 2,716,741 4,290,702
Operating Income -2,878,891 -3,790,250 -2,706,220 -4,292,190
Interest Expense 0 16,764 10,114 5,860
Income Before Tax -2,893,225 -3,824,916 -2,914,204 -4,003,977
Income Tax Expense -136,661 0 -4,551 -4,282,280
Net Income -2,756,427 -3,823,885 -2,909,652 -4,013,883
Per Share
EPS -0.89 -1.71 -1.64 -2.58
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Revenue 6,331 156,419 8,561 0 123,820
Cost of Revenue 59,398 105,829 9,926 0 133,254
Gross Profit -53,067 50,590 -1,365 0 -9,434
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 4,330,028 4,594,743 5,334,287 1,299,936 514,883
Operating Expenses 6,109,830 6,547,063 5,731,396 1,733,679 635,104
Operating Income -6,162,897 -6,496,473 -5,732,760 -1,733,680 -644,538
Interest Expense 58,179 26,878 15,468 15,438 28,643
Income Before Tax -6,203,893 -6,739,120 -5,457,763 -1,749,870 -672,915
Income Tax Expense -136,661 0 -271 -1,774,722 0
Net Income -6,061,247 -6,733,537 -5,457,494 -1,708,827 -650,984
Per Share
EPS -1.96 -3.36 -5.13 -1.50 -0.06
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Assets
Cash and Cash Equivalents 4,228,944 3,589,244 9,352,538 21,756
Short Term Investments 94,190 77,321 49,257 5,999
Net Receivables 30,654 217,843 -24,095 0
Inventory 94,675 60,383 24,095 20,951
Total Current Assets 4,893,655 4,380,252 9,634,013 48,706
Property Plant Equipment 1,533,248 1,103,717 0 0
Goodwill and Intangibles 39,652 49,771 178,403 0
Total Assets 6,426,903 5,483,969 9,812,416 48,706
Liabilities
Account Payables 56,093 45,631 159,908 846,474
Short Term Debt 85,461 47,955 146,250 3,758
Total Current Liabilities 673,207 168,849 908,401 1,245,414
Long Term Debt 291,543 176,345 0 0
Total Liabilities 964,750 345,194 908,401 1,245,414
Shareholders Equity
Retained Earnings -24,589,244 -18,527,997 -11,794,460 -6,336,966
Total Shareholders Equity 5,696,120 5,366,757 9,126,414 -974,578
Balance Sheet (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Assets
Cash and Cash Equivalents 4,228,944 3,589,244 9,352,538 21,756 17,621
Short Term Investments 94,190 77,321 49,257 5,999 0
Net Receivables 30,654 217,843 -24,095 0 928
Inventory 94,675 60,383 24,095 20,951 21,072
Total Current Assets 4,893,655 4,380,252 9,634,013 48,706 39,621
Property Plant Equipment 1,533,248 1,103,717 0 0 0
Goodwill and Intangibles 39,652 49,771 178,403 0 0
Total Assets 6,426,903 5,483,969 9,812,416 48,706 39,621
Liabilities
Account Payables 56,093 45,631 159,908 846,474 217,145
Short Term Debt 85,461 47,955 146,250 3,758 0
Total Current Liabilities 673,207 168,849 908,401 1,245,414 871,435
Long Term Debt 291,543 176,345 0 0 0
Total Liabilities 964,750 345,194 908,401 1,245,414 871,435
Shareholders Equity
Retained Earnings -24,589,244 -18,527,997 -11,794,460 -6,336,966 -4,628,139
Total Shareholders Equity 5,696,120 5,366,757 9,126,414 -974,578 -650,682
Cash Flow Statement (Quarterly) 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Activities
Net Income -6,067,232 -6,739,120 -5,457,494 -1,708,827
Depreciation & Amortization 343,387 103,099 0 0
Stock Based Compensation 365,309 1,011,973 1,734,601 287,442
Change in Working Capital 625,617 -1,120,029 -216,275 644,390
Operating Cash Flow -4,563,576 -6,247,016 -4,179,767 -809,069
Investing Activities
Capital Expenditure -603,890 -1,164,449 -178,403 0
Investments -603,890 -952,497 -178,403 0
Investing Cash Flow -603,890 -1,164,449 -178,403 0
Financing Activities
Debt Repayment -107,756 -206,272 -146,250 0
Common Stock Issued/Repurchased 5,128,186 234 13,654,347 519,613
Dividends Paid 0 0 0 0
Financing Cash Flow 5,807,166 1,648,171 13,688,952 813,205
Summary
Free Cash Flow -5,167,466 -7,411,465 -4,358,170 -809,069
Net Change in Cash 639,700 -5,763,294 9,330,782 4,135
Cash Flow Statement (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Operating Activities
Net Income -6,067,232 -6,739,120 -5,457,494 -1,708,827 -650,984
Depreciation & Amortization 343,387 103,099 0 0 0
Stock Based Compensation 365,309 1,011,973 1,734,601 287,442 0
Change in Working Capital 625,617 -1,120,029 -216,275 644,390 59,611
Operating Cash Flow -4,563,576 -6,247,016 -4,179,767 -809,069 -590,186
Investing Activities
Capital Expenditure -603,890 -1,164,449 -178,403 0 0
Investments -603,890 -952,497 -178,403 0 0
Investing Cash Flow -603,890 -1,164,449 -178,403 0 0
Financing Activities
Debt Repayment -107,756 -206,272 -146,250 0 0
Common Stock Issued/Repurchased 5,128,186 234 13,654,347 519,613 0
Dividends Paid 0 0 0 0 0
Financing Cash Flow 5,807,166 1,648,171 13,688,952 813,205 585,198
Summary
Free Cash Flow -5,167,466 -7,411,465 -4,358,170 -809,069 -590,186
Net Change in Cash 639,700 -5,763,294 9,330,782 4,135 -4,988